<div id="readability-page-1"><p>The Manufacturers Life Insurance Company lifted its holdings in  Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 7.4% during the 4th quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 124,341 shares of the company's stock after purchasing an additional 8,576 shares during the period. The Manufacturers Life Insurance Company owned about 0.21% of Protagonist Therapeutics worth $4,800,000 at the end of the most recent reporting period.</p><ul><li>Are (More) Big Gains Ahead for This Small Cap Biotech Stock?</li></ul><p>A number of other institutional investors and hedge funds also recently made changes to their positions in PTGX. Wellington Management Group LLP lifted its holdings in shares of  Protagonist Therapeutics by 3,025.4% in the fourth quarter. Wellington Management Group LLP now owns 940,077 shares of the company's stock worth $36,287,000 after buying an additional 909,998 shares in the last quarter.  American Century Companies Inc. grew its holdings in shares of  Protagonist Therapeutics by 61.5% in the fourth quarter. American Century Companies Inc. now owns 928,286 shares of the company's stock valued at $35,832,000 after purchasing an additional 353,511 shares in the last quarter.  Principal Financial Group Inc. increased its position in  Protagonist Therapeutics by 3,099.4% in the third quarter. Principal Financial Group Inc. now owns 320,832 shares of the company's stock worth $14,437,000 after purchasing an additional 310,804 shares during the last quarter.  Raymond James Financial Inc. purchased a new stake in  Protagonist Therapeutics during the fourth quarter valued at $11,708,000.  Finally, Pictet Asset Management Holding SA lifted its position in  Protagonist Therapeutics by 3,962.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 296,511 shares of the company's stock valued at $11,445,000 after purchasing an additional 289,213 shares during the last quarter. Hedge funds and other institutional investors own  98.63% of the company's stock. </p><h2>Insider Buying and Selling at Protagonist Therapeutics</h2><p>In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the sale, the chief executive officer now owns 540,260 shares of the company's stock, valued at approximately $20,627,126.80. This represents a 0.98 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the transaction, the insider now directly owns 83,892 shares in the company, valued at approximately $4,676,140.08. The trade was a 26.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 66,532 shares of company stock valued at $3,665,786 in the last ninety days. Corporate insiders own  5.40% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>A number of brokerages recently commented on PTGX. Wedbush  reaffirmed an &#34;outperform&#34; rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a report on Friday, March 28th. The Goldman Sachs Group dropped their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a &#34;neutral&#34; rating for the company in a report on Monday, February 24th. JPMorgan Chase &amp; Co. increased their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, March 4th. JMP Securities  reaffirmed a &#34;market outperform&#34; rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Finally, HC Wainwright  reissued a &#34;buy&#34; rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. Two equities research analysts have rated the stock with a hold rating, seven have issued  a buy rating and one  has assigned  a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $65.44.</p><p><b>Get Our Latest Stock Analysis on PTGX</b></p><h2>Protagonist Therapeutics Trading Up 2.1 %</h2><p>NASDAQ PTGX opened at $43.98 on Friday. The stock has a market cap of $2.72 billion, a PE ratio of 16.53 and a beta of 2.65. Protagonist Therapeutics, Inc. has a 12 month low of $26.79 and a 12 month high of $60.60. The company's 50-day moving average price is $46.87 and its 200-day moving average price is $42.75. </p><p>Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.31. The business had revenue of $28.32 million for the quarter, compared to the consensus estimate of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%.  As a group, sell-side analysts forecast that  Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year. </p><h2>Protagonist Therapeutics Company Profile</h2> (Free Report)<p>Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Protagonist Therapeutics</li><li>How Technical Indicators Can Help You Find Oversold Stocks </li><li>IBM's AI Offensive: Assessing IBM's Path to Renewed Growth</li><li>Pros And Cons Of Monthly Dividend Stocks</li><li>Rockwell Automation: Tailwinds From Onshoring U.S. Production</li><li>The Most Important Warren Buffett Stock for Investors: His Own</li><li>Is Energy Transfer Undervalued or a Value Trap?</li></ul><p><strong>Want to see what other hedge funds are holding PTGX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Protagonist Therapeutics Right Now?</h2><p>Before you consider Protagonist Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.</p><p>While Protagonist Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PTGX

<p>The Manufacturers Life Insurance Company increased its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 7.4%, acquiring an additional 8,576 shares, bringing its total to 124,341 shares valued at approximately $4.8 million. Other institutional investors also significantly raised their holdings. Insider trading included CEO Dinesh V. Ph D. Patel selling 5,359 shares. Analysts have mixed ratings on PTGX, with price targets ranging from $38 to $80, reflecting a consensus rating of "Moderate Buy." The stock is currently trading at $43.98, with a market cap of $2.72 billion.</p>

The Manufacturers Life Insurance Company Purchases 8,576 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)